Torrent Pharma

Why is Torrent Pharmaceuticals Ltd. falling/rising?

As of 22-Jun, Torrent Pharmaceuticals Ltd. is seeing a stock price increase to 4,457.75, following a trend reversal after five days of decline, with a year-to-date rise of 16.04%. Increased investor participation and strong fundamentals, including a high ROCE and low debt ratio, support this positive market sentiment.

As of 22-Jun, Torrent Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 4,457.75, with an increase of 31.05 (0.7%). This upward movement follows a trend reversal after five consecutive days of decline, indicating a potential shift in market sentiment. Additionally, the stock has shown a significant year-to-date increase of 16.04%, outperforming the Sensex, which has declined by 9.54% during the same period. <BR><BR>Investor participation has also risen, as evidenced by a notable increase in delivery volume, which surged by 117.69% against the five-day average. This suggests growing interest and confidence among investors. Furthermore, the stock's performance is supported by strong fundamentals, including high management efficiency reflected in a return on capital employed (ROCE) of 21.88% and a low debt to EBITDA ratio of 3.30 times, indicating a strong ability to service debt. <BR><BR>Despite underperforming its sector by 0.64% today, the overall positive factors, including consistent returns over the past three years and high institutional holdings at 25.25%, contribute to the stock's rising price. These institutional investors typically have better resources to analyze company fundamentals, which may further bolster confidence in the stock.

Which are the latest news on Torrent Pharma?

How big is Torrent Pharma?

As of 10th June, Torrent Pharmaceuticals Ltd. has a market capitalization of 152,131.00 Cr, with recent net sales of 13,980.00 Cr and a net profit of 2,138.00 Cr. The company has shareholder's funds of 8,388.43 Cr and total assets of 43,613.69 Cr.

As of 10th June, Torrent Pharmaceuticals Ltd. has a market capitalization of 152,131.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Torrent Pharmaceuticals reported Net Sales of 13,980.00 Cr and a Net Profit of 2,138.00 Cr.<BR><BR>For the latest annual period ending in March 2026, the company has Shareholder's Funds amounting to 8,388.43 Cr and Total Assets of 43,613.69 Cr.

Who are in the management team of Torrent Pharma?

The management team of Torrent Pharma includes key individuals such as Samir Mehta (Executive Chairman), Sudhir Mehta (Chairman Emeritus), and several independent directors, along with operational and compliance leadership. This diverse team provides strong expertise and guidance for the company.

The management team of Torrent Pharma includes the following key individuals:<BR><BR>1. **Sudhir Mehta** - Chairman Emeritus<BR>2. **Samir Mehta** - Executive Chairman<BR>3. **Shailesh Haribhakti** - Independent Director<BR>4. **H Khaitan** - Independent Director<BR>5. **Ameera Shah** - Independent Director<BR>6. **Nayantara Bali** - Independent Director<BR>7. **Jinesh Shah** - Director (Operation)<BR>8. **Maurice Chagnaud** - Independent Director<BR>9. **Aman Mehta** - Whole Time Director<BR>10. **Manish Choksi** - Independent Director<BR>11. **Chintan Trivedi** - Company Secretary & Compliance Officer<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the peers of the Torrent Pharma?

Torrent Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Zydus Lifesciences, Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs, and Biocon. Torrent Pharma has a 1-year return of 42.91%, outperforming its peers, with notable management and capital structure ratings among them.

Peers: The peers of Torrent Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs, and Biocon.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, and Laurus Labs, while Average management risk is found at Aurobindo Pharma and Biocon. Growth is Excellent for Sun Pharma.Inds., Zydus Lifesci., Lupin, and Mankind Pharma, while Average growth is seen at Torrent Pharma, and Below Average growth is noted for Divi's Lab., Cipla, Aurobindo Pharma, and Laurus Labs. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, Zydus Lifesci., Dr Reddy's Labs, and Mankind Pharma, while Good capital structure is found at Torrent Pharma and Lupin, and Average capital structure is noted for Aurobindo Pharma and Laurus Labs.<BR><BR>Return Snapshot: Torrent Pharma has a 1-year return of 42.91%, which is higher than the highest peer return of 42.91% from Torrent Pharma itself and significantly higher than the lowest peer return of -8.98% from Cipla. Additionally, the peers with negative six-month returns include Cipla and Dr Reddy's Labs.

What does Torrent Pharma do?

Torrent Pharmaceuticals Ltd. is a major Indian pharmaceutical company specializing in chronic and sub-chronic therapeutic segments, with a market cap of INR 152,131 Cr and recent net sales of 4,197 Cr and net profit of 364 Cr as of March 2026. The company is known for its niche pharmaceutical solutions and has a P/E ratio of 68.00.

Overview:<BR>Torrent Pharmaceuticals Ltd. is a leading player in the Indian pharmaceutical sector, focusing on chronic and sub-chronic therapeutic segments within the Pharmaceuticals & Biotechnology industry and categorized as a Large Cap company.<BR><BR>History:<BR>Torrent Pharmaceuticals Ltd. was incorporated in an unspecified year and has established itself as a leader in developing niche pharmaceutical solutions. The latest quarterly results reported are for March 2026, showcasing significant sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4,197 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 364 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 152,131 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 68.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.85% <BR>Debt-Equity: 1.55 <BR>Return on Equity: 26.24% <BR>Price-to-Book: 18.02 <BR><BR>Contact Details:<BR>Address: Torrent House, Off Ashram Road Ahmedabad Gujarat : 380009 <BR>Phone: 91-79-26599000 <BR>Email: investorservices@torrentpharma.com <BR>Website: http://www.torrentpharma.com

Are Torrent Pharmaceuticals Ltd. latest results good or bad?

Torrent Pharmaceuticals Ltd.'s latest results show strong revenue growth with a record ₹4,197 crores for Q4 FY26, but a significant net profit decline of 42.68% raises concerns about margin sustainability. While revenue growth is positive, the profit drop suggests caution for investors.

Torrent Pharmaceuticals Ltd.'s latest results present a mixed picture. On one hand, the company achieved a record revenue of ₹4,197 crores for Q4 FY26, reflecting a strong sequential growth of 27.07% and a year-on-year increase of 41.84%. This growth was driven by market share gains in key therapeutic segments such as cardiovascular and anti-diabetes.<BR><BR>However, the net profit saw a significant decline, dropping by 42.68% quarter-on-quarter to ₹364 crores, and down 26.91% year-on-year. This sharp profit drop raises concerns about the sustainability of the company's margins, particularly due to an extraordinary surge in interest expenses and depreciation costs.<BR><BR>The operating margin also compressed slightly to 32.85%, indicating some operational pressure despite strong revenue growth. The return on equity remains robust at 25.66%, showcasing the company's capital efficiency.<BR><BR>Overall, while the revenue growth is a positive sign, the substantial profit decline and the exceptional charges raise questions about the quality of earnings and the company's financial health moving forward. Investors may need to approach with caution, given the mixed signals from the latest results.

Should I buy, sell or hold Torrent Pharmaceuticals Ltd.?

Is Torrent Pharma technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bullish, supported by daily moving averages and weekly MACD, but tempered by mildly bearish monthly indicators and market indecision.

As of 1 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum and the weekly MACD also showing a bullish signal. However, the monthly MACD and KST are mildly bearish, suggesting some caution. Bollinger Bands are bullish on both weekly and monthly time frames, supporting the overall positive outlook. The lack of clear trends in Dow Theory and OBV indicates some indecision in the market. Overall, while there are bullish indicators, the presence of mildly bearish signals suggests a tempered bullish sentiment.

How has been the historical performance of Torrent Pharma?

Torrent Pharma has shown consistent growth in net sales and profits, with net sales increasing from INR 7,673 crore in March 2019 to INR 11,516 crore in March 2025, and profit after tax rising from INR 436 crore to INR 1,911 crore during the same period. The company also improved its operating profit margin to 32.88% and maintained a solid balance sheet.

Answer:<BR>The historical performance of Torrent Pharma shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Torrent Pharma's net sales have steadily increased from INR 7,673.00 crore in March 2019 to INR 11,516.00 crore in March 2025. The total operating income followed a similar trend, rising from INR 7,673.00 crore in March 2019 to INR 11,516.00 crore in March 2025. The company's operating profit (PBDIT) also saw growth, climbing from INR 2,041.00 crore in March 2019 to INR 3,744.00 crore in March 2025, reflecting an improving operating profit margin that reached 32.88% in March 2025. Profit before tax increased from INR 562.00 crore in March 2019 to INR 2,673.00 crore in March 2025, while profit after tax rose from INR 436.00 crore to INR 1,911.00 crore during the same period, resulting in a PAT margin of 16.89% in March 2025. On the balance sheet, total assets increased from INR 13,576.53 crore in March 2020 to INR 14,395.59 crore in March 2025, while total liabilities decreased from INR 14,505.45 crore in March 2024 to INR 14,395.59 crore in March 2025. The cash flow from operating activities showed a positive trend, reaching INR 2,585.00 crore in March 2025, although the net cash flow reflected an outflow of INR 261.00 crore in the same year. Overall, Torrent Pharma has demonstrated strong growth in revenue and profitability, alongside a solid balance sheet position.

When is the next results date for Torrent Pharma?

The next results date for Torrent Pharma is November 7, 2025.

The next results date for Torrent Pharma is scheduled for November 7, 2025.

Who are the top shareholders of the Torrent Pharma?

The top shareholders of Torrent Pharma include Torrent Investments Limited with 68.31%, followed by institutional investors such as mutual funds at 5.03% and foreign institutional investors at 16.31%. The highest public shareholder is NPS Trust at 1.8%, while individual investors hold 4.51% of the shares, with no pledged promoter holdings reported.

The top shareholders of Torrent Pharma are primarily the promoters, with Torrent Investments Limited holding the largest share at 68.31%. Additionally, institutional investors play a significant role, with 38 mutual funds collectively holding 5.03% and 819 foreign institutional investors (FIIs) holding 16.31%. The highest public shareholder is NPS Trust, which holds 1.8%, while individual investors account for 4.51% of the shares. There are no pledged promoter holdings reported.

Is Torrent Pharma overvalued or undervalued?

As of January 12, 2024, Torrent Pharma is considered very expensive and overvalued, with a PE Ratio of 55.29 and an EV to EBITDA of 29.34, significantly higher than its peers like Sun Pharma and Cipla, despite a strong historical performance.

As of 12 January 2024, Torrent Pharma's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market positioning. The company is currently considered overvalued. Key ratios include a PE Ratio of 55.29, an EV to EBITDA of 29.34, and a PEG Ratio of 2.63, all of which are substantially higher than industry norms.<BR><BR>In comparison to its peers, Torrent Pharma's valuation metrics stand out unfavorably; for instance, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla boasts a more attractive PE of 22.99 and an EV to EBITDA of 15.93. The elevated ratios suggest that Torrent Pharma is priced at a premium compared to its competitors, reinforcing the conclusion of overvaluation. Despite a strong historical performance, including a 10.86% return over the past year compared to the Sensex's 7.65%, the current valuation does not align with its financial fundamentals.

What is the bonus history of the Torrent Pharma?

Torrent Pharmaceuticals has issued bonuses to shareholders, with the most recent being a 1:1 bonus on July 8, 2022, and a previous 1:1 bonus on July 23, 2013. This practice demonstrates the company's commitment to rewarding its shareholders.

Torrent Pharmaceuticals has a history of issuing bonuses to its shareholders. The most recent bonus was a 1:1 bonus issue, which was announced with an ex-date of July 8, 2022, and a record date of July 11, 2022. Prior to that, the company also issued a 1:1 bonus on July 23, 2013, with a record date of July 24, 2013. This consistent practice of bonus issues reflects the company's commitment to rewarding its shareholders.

Has Torrent Pharma declared dividend?

Yes, Torrent Pharmaceuticals Ltd. has declared a 520% dividend, amounting to ₹26 per share, with an ex-date of January 31, 2025. The company has shown strong total returns over various periods, particularly in the long term.

Torrent Pharmaceuticals Ltd. has declared a 520% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 520%<BR>- Amount per share: 26 per share<BR>- Ex-date: 31 Jan 25<BR><BR>Dividend Yield: 1.02%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -5.18%, the dividend return was 0.78%, resulting in a total return of -4.4%.<BR><BR>For the 1-year period, the price return was 13.48%, the dividend return was 1.12%, leading to a total return of 14.6%.<BR><BR>Over the 2-year period, the price return was 76.44%, the dividend return was 3.34%, culminating in a total return of 79.78%.<BR><BR>In the 3-year period, the price return was 127.44%, the dividend return was 5.39%, resulting in a total return of 132.83%.<BR><BR>For the 4-year period, the price return was 124.57%, the dividend return was 7.42%, leading to a total return of 131.99%.<BR><BR>In the 5-year period, the price return was 166.6%, the dividend return was 12.25%, culminating in a total return of 178.85%.<BR><BR>Overall, Torrent Pharmaceuticals has declared a substantial dividend, and the total returns over various periods indicate strong performance, particularly in the longer term, suggesting a positive outlook for investors.